Swisscanto leads USD 25 million growth financing for Piomic Medical
Piomic Medical, a Swiss medtech start‑up focused on complex tissue healing, closed a USD 25 million growth financing led by Swisscanto. The proceeds will fund the completion of its current clinical development program, including the MAVERICKS IDE pivotal trial and the NAZARÉ trial, U.S. market approval filing, and market entry for the COMS One Therapy System. The financing also supports expansion of the COMS platform into future applications.
Piomic Medical, a Swiss medtech start‑up focused on complex tissue healing, closed a USD 25 million growth financing led by Swisscanto. The proceeds will fund the completion of its current clinical development program, including the MAVERICKS IDE pivotal trial and the NAZARÉ trial, U.S. market approval filing, and market entry for the COMS One Therapy System. The financing also supports expansion of the COMS platform into future applications.
This financing does not directly involve AI, but it reflects Switzerland’s strong support for advanced medical technologies.
Original source record. Open the original record to verify the underlying announcement.